Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending Brukinsa (zanubrutinib) for the treatment of eligible adult patients with:
- Untreated chronic lymphocytic leukaemia if there is a 17p deletion or TP53 mutation (high risk) or
- Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation, and fludarabine-cyclophosphamide-rituximab or bendamustine plus rituximab is unsuitable and
- Relapsed or refractory chronic lymphocytic leukaemia
Brukinsa is the third Bruton's tyrosine kinase inhibitor for patients with chronic lymphocytic leukaemia to be recommended by NICE for routine commissioning.
